Shoreline Biosciences is developing the next generation of cellular immunotherapies to win the war on cancer. Natural killer cells and macrophages are immune cells that play an important role in tumor responses. Using their expertise in iPSC differentiation, genetic engineering and immune cell biology, Shoreline is building a pipeline of iPSC-derived natural killer cells (iNKs) and macrophages (iMACs). Both iNKs and iMACs will be developed as ‘off-the-shelf’ to design the therapies for durability, scalability, safety and efficacy. The iPSC system is modular, enabling Shoreline to tailor each program and develop a robust pipeline.

Shoreline Biosciences

 Scientist II – Shoreline Biosciences – San Diego, CA – San Diego Biotechnology Network 

Shoreline Biosciences Announces $43M Financing To Advance Pipeline Of Allogeneic Natural Killer And Macrophage Cellular Immunotherapies Derived From Pluripotent Stem Cells - PR Newswire

 Shoreline Biosciences raises $43M to advance allogenic NK and macrophage cell therapies 

Beigene expands into cancer cell therapy with Shoreline pact - BioPharma Dive

 Shoreline Biosciences Appoints Kimberly Manhard To Board Of Directors 

 Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires 

 Shoreline Biosciences Appoints Robert Hollingsworth, Ph.D., As Chief Scientific Officer 

Shoreline welcomes Robert Hollingsworth as CSO - The Science Board

 Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using … 

 Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies 

The Shoreline Biosciences, Inc. team will present at the upcoming 2024 Stifel Healthcare Conference, which will be held on November 18-19, 2024, in New York, NY. We invite you to attend our presentation to learn more about Shoreline’s approach to developing disease-modifying iNK cell therapies for autoimmune disorders.

https://lnkd.in/gDDYXFPH

#Biotech #CellTherapy #Autoimmunity

Shoreline Biosciences Presents Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells - PR Newswire

On the Lookout: Prometheus Veterans Launch Mirador Therapeutics With $400 Million - Genetic Engineering & Biotechnology News

 Shoreline Biosciences Appoints Mohammad El-Kalay, Ph.D. As Senior VP And Head Of CMC 

Shoreline Launches into "Era of Cell Therapy" with $4 Billion in Partnerships - BioSpace

Podcast: Life beyond Provenge as Dendreon enters CDMO world - BioProcess Insider

From everyone at Shoreline Biosciences, Inc., we would like to #givethanks and wish everyone a happy Thanksgiving filled with gratitude and happiness.

#HappyThanksgiving

Gilead's Kite makes off-the-shelf play with Shoreline Biosciences CAR-NK deal worth as much as $2.3B - Fierce Biotech

Shoreline Biosciences - The Pharma Letter

Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference

Shoreline Biosciences to Present at 2024 Stifel Healthcare Conference

 Fate Therapeutics Inc. v. Shoreline Biosciences Inc. 

 Shoreline Biosciences To Present At Two Upcoming Investor Conferences 

Editas Makes Good on Portfolio Reprioritization with Shoreline Deals (Updated) - BioSpace


				Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies			

Editas, in next restructuring step, to sell cell therapy work to Shoreline - BioPharma Dive

Meet Suping Peng, our dedicated senior scientist in our Natural Killer Cell group here at Shoreline Biosciences, Inc. Each member of our team is driven by a shared passion to develop groundbreaking products that will positively impact patients' lives. Suping firmly believes that our collective efforts here at Shoreline will be instrumental in driving global change.

Outside of her professional endeavors, Suping finds joy in exploring new destinations, indulging in hikes, and commuting to work on her bike daily. However, her greatest joy stems from spending quality time with her two-year-old daughter, Rosie. As a dedicated mother, Suping humorously remarks that she should earn an additional degree in motherhood, perhaps a master’s degree at the very least.

Join our team today: https://lnkd.in/gQC7unzw

#CellTherapy #OncologyResearch #Immunotherapies #Biotech #EmployeeSpotlight #RegenerativeMedicine #Autoimmunity

 Scope of Issued Patents May be Limited by Prosecution Estoppel Created in Child Cases 

SHORELINE BIOSCIENCES ANNOUNCES APPOINTMENT OF CELL THERAPY MANUFACTURING VETERAN CHARLES CALDERARO III AS CHIEF TECHNICAL OFFICER - PR Newswire

 SHORELINE BIOSCIENCES TO PRESENT AT 2024 STIFEL HEALTHCARE CONFERENCE 

 BeiGene and Shoreline sever ties 

Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer - MedCity News

 Shoreline to collaborate with Kite in a deal that could top $2B 

From all of us at Shoreline Biosciences, Inc., we'd like to wish you a holiday season filled with health, joy and success!

Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies - PR Newswire

 iPSC biotech Shoreline Biosciences wins patent infringement suit over Fate, Whitehead Institute 

 Methods and compositions for generating chimeric antigen receptor-monocytes/ … 

 Chimeric antigen receptors for natural killer cells and uses thereof in … 

 Shoreline Biosciences Names Chief Business Officer 

 Gilead's Kite makes off-the-shelf play with Shoreline Biosciences CAR-NK deal worth as much as $2.3B 

SHORELINE BIOSCIENCES WINS A COMPREHENSIVE SUMMARY JUDGEMENT VICTORY ON ALL CLAIMS BROUGHT BY FATE THERAPEUTICS AND WHITEHEAD INSTITUTE ON IPSC GENERATION AND USE - PR Newswire

SHORELINE BIOSCIENCES TO PRESENT AT 2024 STIFEL HEALTHCARE CONFERENCE - PR Newswire

 Shoreline Biosciences Appoints Scott Forrest, Ph.D., As Chief Business Officer 

Editas finds buyer for iNK programs 10 days after clearing out pipeline - Fierce Biotech


				Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer			

Meet Chad Viergever, our Senior Manager of Corporate Development at Shoreline Biosciences, Inc. Originally from Sacramento, CA, Chad's journey led him to San Diego, where he found a love for the area and a passion for the life sciences.

Chad's passion for cell therapy stems from a personal experience. Witnessing his grandfather's battle with lung cancer has fueled Chad's determination to make a meaningful impact in the field. His mission extends beyond scientific advancement; he aims to revolutionize treatment accessibility for a broader spectrum of patients, prioritizing cost-effectiveness and reproducibility. Inspired by Shoreline's culture of collaboration and innovation, Chad thrives in an environment that fosters growth and creativity. Plus, he's a big fan of our snack selection!

Fun facts about Chad: he's distantly related to Meriwether Lewis and recently became a first-time parent. Outside work, you can find him diving into fantasy fiction, strumming his guitar, or spending time at the beach with his family.

Every day, Chad's work is fueled by memories of his grandfather and the desire to make a difference in the lives of patients and families everywhere. Join us in celebrating Chad's dedication and passion for making a positive impact.
Join our team today: https://lnkd.in/gQC7unzw

#CellTherapy #OncologyResearch #Immunotherapies #Biotech #EmployeeSpotlight #RegenerativeMedicine #Autoimmunity

Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells

 Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies 


				Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells			

 Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies 

https://shorelinebio.com/

Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciences - Fierce Biotech

BeiGene ends pact with Shoreline, its ‘entry into cell therapy’ - Endpoints News

Meet Jennifer L., our invaluable senior scientist in our analytical development group here at Shoreline Biosciences, Inc. Jen is dedicated to turning the brilliant ideas of our research team into life-saving cancer treatments, all while adding her unique touch of fun and charm to her work.
 
At Shoreline, innovation is at the core of our culture, and Jen is thrilled to be a part of a company that shares her commitment to finding a cure for cancer.
 
From a young age, Jen was introduced to the world of engineering, which ignited her interest in learning more and problem-solving. Her passion for understanding biology led her down the path of biotechnology, life sciences, and stem cell therapeutics.
 
When she's not in the lab, Jen is typically outside hiking and camping or mastering the game of golf and learning how not to be terrible (her words, not ours!). She's constantly striving to improve and enjoys the challenge. In her downtime, she indulges in her guilty pleasure - reality TV. Despite her husband's disinterest, Jen enjoys watching all kinds of reality shows, especially The Bachelor.
 
But beyond her hobbies, Jen's true love, aside from her husband, is their beloved dog, Parkie. She's absolutely obsessed with Parkie and has an impressive collection of photos to prove it.
 
Join our team today: https://lnkd.in/gQC7unzw
 
#CellTherapy #OncologyResearch #Immunotherapies #Biotech #EmployeeSpotlight #RegenerativeMedicine #Autoimmunity

Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies - Business Wire

 Editas names Biogen veteran as top scientist in latest ... 

 Shoreline Biosciences to Present at Upcoming Investor Conferences 

 Shoreline Biosciences Finds $140M 

Shoreline Biosciences

Business:

About: